Suppr超能文献

囊性纤维化肺病中趋化因子信号传导失调:一个潜在的治疗靶点。

Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.

作者信息

Guan Xiaoqing, Hou Yuning, Sun Fei, Yang Zhe, Li Chunying

机构信息

Department of Biochemistry and Molecular Biology, Wayne State University School of Medicine. 540 E. Canfield Avenue, 5312 Scott Hall, Detroit, MI 48201, USA.

出版信息

Curr Drug Targets. 2016;17(13):1535-44. doi: 10.2174/1389450117666151209120516.

Abstract

CF lung disease is characterized by a chronic and non-resolving activation of the innate immune system with excessive release of chemokines/cytokines including IL-8 and persistent infiltration of immune cells, mainly neutrophils, into the airways. Chronic infection and impaired immune response eventually lead to pulmonary damage characterized by bronchiectasis, emphysema, and lung fibrosis. As a complete knowledge of the pathways responsible for the exaggerated inflammatory response in CF lung disease is lacking, understanding these pathways could reveal new therapeutic targets, and lead to novel treatments. Therefore, there is a strong rationale for the identification of mechanisms and pathways underlying the exaggerated inflammatory response in CF lung disease. This article reviews the role of inflammation in the pathogenesis of CF lung disease, with a focus on the dysregulated signaling involved in the overexpression of chemokine IL-8 and excessive recruitment of neutrophils in CF airways. The findings suggest that targeting the exaggerated IL-8/IL-8 receptor (mainly CXCR2) signaling pathway in immune cells (especially neutrophils) may represent a potential therapeutic strategy for CF lung disease.

摘要

囊性纤维化肺部疾病的特征是先天性免疫系统的慢性且无法消退的激活,伴有趋化因子/细胞因子(包括白细胞介素-8)的过度释放,以及免疫细胞(主要是中性粒细胞)持续浸润到气道中。慢性感染和免疫反应受损最终导致以支气管扩张、肺气肿和肺纤维化为特征的肺部损伤。由于缺乏对导致囊性纤维化肺部疾病中过度炎症反应的途径的全面了解,了解这些途径可能会揭示新的治疗靶点,并带来新的治疗方法。因此,有充分的理由去识别囊性纤维化肺部疾病中过度炎症反应背后的机制和途径。本文综述了炎症在囊性纤维化肺部疾病发病机制中的作用,重点关注参与趋化因子白细胞介素-8过表达和囊性纤维化气道中中性粒细胞过度募集的失调信号传导。研究结果表明,针对免疫细胞(尤其是中性粒细胞)中过度的白细胞介素-8/白细胞介素-8受体(主要是CXCR2)信号通路可能是囊性纤维化肺部疾病的一种潜在治疗策略。

相似文献

1
Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.
Curr Drug Targets. 2016;17(13):1535-44. doi: 10.2174/1389450117666151209120516.
2
Harnessing Neutrophil Survival Mechanisms during Chronic Infection by : Novel Therapeutic Targets to Dampen Inflammation in Cystic Fibrosis.
Front Cell Infect Microbiol. 2017 Jun 30;7:243. doi: 10.3389/fcimb.2017.00243. eCollection 2017.
3
The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Expert Opin Ther Targets. 2018 Aug;22(8):687-701. doi: 10.1080/14728222.2018.1501361. Epub 2018 Jul 26.
4
Current Concepts and Controversies in Innate Immunity of Cystic Fibrosis Lung Disease.
J Innate Immun. 2016;8(6):531-540. doi: 10.1159/000446840. Epub 2016 Jul 1.
5
Interleukin-17 Pathophysiology and Therapeutic Intervention in Cystic Fibrosis Lung Infection and Inflammation.
Infect Immun. 2016 Aug 19;84(9):2410-21. doi: 10.1128/IAI.00284-16. Print 2016 Sep.
6
Innate immunity in cystic fibrosis lung disease.
J Cyst Fibros. 2012 Sep;11(5):363-82. doi: 10.1016/j.jcf.2012.07.003. Epub 2012 Aug 20.
8
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.
J Cyst Fibros. 2015 Jul;14(4):419-30. doi: 10.1016/j.jcf.2015.03.003. Epub 2015 Mar 23.
10
Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung disease.
Am J Respir Crit Care Med. 2015 Apr 15;191(8):902-13. doi: 10.1164/rccm.201409-1610OC.

引用本文的文献

1
miRNA-target gene network analysis in siblings with cystic fibrosis and phenotypic variability.
Turk J Med Sci. 2025 Apr 28;55(4):1014-1023. doi: 10.55730/1300-0144.6054. eCollection 2025.
4
Targeting the MEK1/2 pathway to combat infection and inflammation in cystic fibrosis.
mBio. 2025 Jul 9;16(7):e0077525. doi: 10.1128/mbio.00775-25. Epub 2025 May 27.
6
Neutrophil-Derived Proteases in Lung Inflammation: Old Players and New Prospects.
Int J Mol Sci. 2024 May 17;25(10):5492. doi: 10.3390/ijms25105492.
10
MSCs interaction with the host lung microenvironment: An overlooked aspect?
Front Immunol. 2022 Nov 15;13:1072257. doi: 10.3389/fimmu.2022.1072257. eCollection 2022.

本文引用的文献

1
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR.
N Engl J Med. 2015 Oct 29;373(18):1783-4. doi: 10.1056/NEJMc1510466.
2
Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Ther Adv Respir Dis. 2015 Dec;9(6):313-26. doi: 10.1177/1753465815601934. Epub 2015 Sep 28.
3
Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy.
J Cyst Fibros. 2015 Jul;14(4):419-30. doi: 10.1016/j.jcf.2015.03.003. Epub 2015 Mar 23.
4
Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor.
J Cyst Fibros. 2016 Jan;15(1):67-73. doi: 10.1016/j.jcf.2015.02.010. Epub 2015 Mar 11.
5
The low PLC-δ1 expression in cystic fibrosis bronchial epithelial cells induces upregulation of TRPV6 channel activity.
Cell Calcium. 2015 Jan;57(1):38-48. doi: 10.1016/j.ceca.2014.11.005. Epub 2014 Nov 18.
6
The protein kinases TPL2 and EGFR contribute to ERK1/ERK2 hyper-activation in CFTRΔF508-expressing airway epithelial cells exposed to Pseudomonas aeruginosa.
Biochem Biophys Res Commun. 2013 Nov 22;441(3):689-692. doi: 10.1016/j.bbrc.2013.10.030. Epub 2013 Oct 25.
8
10
The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment.
J Cell Mol Med. 2014 Feb;18(2):218-30. doi: 10.1111/jcmm.12153. Epub 2013 Nov 25.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验